Skip to main content

Table 1 Overall and per-treatment-group patient baseline characteristics

From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Baseline characteristics

Overall no. of patients (%)

Arm A (%)

Arm B (%)

Arm C (%)

Total

19

5

8

6

Age

    

 Median

60

51

57.5

61.5

 Range

27–86

27–71

50–86

47–77

Sex

    

 Male

6 (32)

1 (20)

4 (50)

1 (17)

 Female

13 (68)

4 (80)

4 (50)

5 (83)

ECOG Performance Status

    

 0

10

2

4

4

 1

9

3

4

2

Stage at Trial Entry

    

 No evidence of disease

4 (21)

2 (40)

0 (0)

2 (33)

 Locally advanced

1 (5)

0 (0)

0 (0)

1 (17)

 Metastatic*

14 (74)

3 (60)

8 (100)

3 (50)

Prior Therapy

    

 Chemotherapy alone

5

1

3

1

 Chemotherapy/RT alone

2

0

1

1

 Surgery total

12

4

4

4

  Surgery followed by chemotherapy

7

3

2

2

5

1

2

2

  Surgery followed by chemo/RT

Prior surgical resection

    

 Yes

12 (63)

4 (80)

4 (50)

4 (67)

 No

7 (37)

1 (20)

4 (50)

2 (33)

Serum CEA at trial initiation (ng/mL)

    

 Median

4.8

5.3

4.65

7.95

 Range

1–246.7

1.1–34.2

2.1–246.7

1–18.1

Serum CA-19-9 at trial initiation (ng/mL)

    

 Median

532

22

1067

27

 Range

3–96,900

3–2,710

3–96,900

3–30,300

  1. Abbreviation: Chemo/RT = chemotherapy in combination with radiation;
  2. * All received previous chemotherapy.